Results 281 to 290 of about 71,305 (341)

C1q neutralization during epileptogenesis attenuates complement‐mediated synaptic elimination and epileptiform activity

Epilepsia, EarlyView.
Abstract Objective Accumulating evidence indicates that aberrant C1q‐C3 complement signaling in microglia and astrocytes drives synaptic dysfunction and neuronal loss. C1q‐mediated synaptic dysfunction disrupts neuronal circuitry balance and can lead to network hyperexcitability in epilepsy.
Yoonyi Jeong, Hyun‐Kyoung Lim, Hayeon Kim, Juheon Lee, Siyoon Lee, Minah Suh   +5 more
wiley   +1 more source

Some effects of anticonvulsant drugs on sugar uptake by cerebral cortex slices

, 1972
Peter H. Gray
openalex   +1 more source

Zebrafish models of developmental epileptic encephalopathy accurately reflect clinical electrographic biomarkers

Epilepsia, EarlyView.
Abstract Objective Developmental epileptic encephalopathies (DEEs) are epilepsy conditions characterized by significant severity and treatment challenges. Spectral components of the encephalogram (EEG) may provide a valuable biomarker of epileptic severity.
Paige Whyte‐Fagundes, Joseane Righes Marafiga, Bingyao Zhu, Scott C. Baraban   +3 more
wiley   +1 more source

Clinical Insights Into the Mechanistic Crossroads of Lamotrigine and Therapeutic Ketosis in Bipolar Depression. [PDF]

Biol Psychiatry Glob Open Sci
Ali DN, Campbell IH, Leung JG, Gonzalez Campos T, Liu D, Ercis M, Markota M, Ceylan D, Lara-Breitinger K, Lopez-Jimenez F, Anderson AS, Ozerdem A, Winham SJ, Frye MA.   +13 more
europepmc   +1 more source

Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial (PACIFIC)

Epilepsia, EarlyView.
Abstract Objective This randomized, double‐blind, phase 1b/2a clinical trial was designed to evaluate the safety, tolerability, and efficacy of oral bexicaserin versus placebo for the treatment of seizures in adolescents and adults with developmental and epileptic encephalopathies (DEEs).
Dennis J. Dlugos, Ingrid E. Scheffer, Jacqueline A. French, David G. Vossler, Chad Orevillo, Shikha Polega, Randall Kaye, and the LP352‐201 Study Investigators, Kore Liow, Ena Zhu, Jennifer Waldron, Hayley Groubert, Alexis Anderson, Pavel Klein, Salman Hashmi, Shicong Ye, Anita Farhi, David Vossler, Dione M. Froman, Shannon L. Hoffman‐Huffaker, Ki Hyeong Lee, AnnaLyn Dallas, Amir Arain, Laura Beeler, Michael Macken, Irena Bellinski, Elizabeth Cunningham, James Renfroe, Shezsay Colbert, Robert Hogan, Patty Schaefer, Susan Shaw, Sheetal Desai, Ahmed Sadek, Haile Robertson, Kamil Detyniecki, Anabela Cieslicki, Ruben Kuzniecky, Sarah Goodman, Selim Benbadis, Marina Azevedo, Sami Aboumatar, Julie Biel, Nilika Singhal, Emerald Wan, Evan Fertig, Hannah Hart, Debopam Samanta, Sarah Hankins, Steven Wolf, Patricia Pena, Robert Nahouraii, M. J. Mari, David Burdette, Stephanie Mueller, Karen Keough, Victoria Henderson, Talitha Durgin, Terence O’Brien, Rafael Smith, Jack Germaine, Kate Riney, Lori Anthony, David Reutens, Kimberley Irwin, Michael Fahey, Melissa Batt, Stephanie Kaladis, Kasthoori Jeyachanthiran, Ingrid Scheffer, Rebecca Wharrie, Greesha Zacharia, Brittany Walsh, Heather Robinson, Sharon Ganter   +74 more
wiley   +1 more source

Carvone derived cannabidiol enantiomers as novel anticonvulsants. [PDF]

Neuropsychopharmacology
Hines RM, Contreras A, Carrillo A, Paton A, Tenorio AJ, Maio WA, Hines DJ.   +6 more
europepmc   +1 more source

Repurposing medications to prevent psychosis. [PDF]

Npj Ment Health Res
Cohen BM, McPhie DL, Sonntag KC, Lopes C, Babb SM.   +4 more
europepmc   +1 more source

Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events. [PDF]

J Immunother Cancer
Khattab S, Wan G, Xu S, Moseley C, Tran M, Beagles E, Lin C, Leung BW, Azin M, Hao N, Reynolds KL, Demehri S, LeBoeuf NR, Semenov YR.   +13 more
europepmc   +1 more source

Study of anticonvulsant properties of 1,2,4-triazole derivatives and prospects for their use in pharmacy

N. M. Borysenko, В. В. Парченко, І. V. Bushueva, О. К. Yerenko   +3 more
openalex   +2 more sources

Advancing drug safety in psychiatry: insights from pharmacogenomics of hypersensitivity reactions. [PDF]

Front Pharmacol
Alhaj HA, Samara J, Alnamous A, Karima R, Saber-Ayad M.   +4 more
europepmc   +1 more source